All In Biotech

Drug Trial Radar · NCT03345914

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Aug 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 367 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

367

Actual

Start

Nov 17, 2017

Primary completion

Jun 20, 2019

Study completion Sep 10, 2019

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Nov 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to \<12 years of age with severe atopic dermatitis (AD). The secondary objective is to assess the safety of dupilumab administered concomitantly with TCS in patients ≥6 years to \<12 years of age with severe AD.

Conditions

  • Dermatitis, Atopic

Interventions

  • DupilumabDrug

    Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous (SC)

  • Matching PlaceboDrug

    Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)

  • Background Treatment: Topical CorticosteroidsOther

    All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.

  • Background Treatment: MoisturizersOther

    All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16Time frame: Week 16

Locations

61 sites in 6 countries. Site status is shown where the registry gives one.

  • Regeneron Research Site

    Birmingham, Alabama

  • Regeneron Research Site

    Gilbert, Arizona

  • Regeneron Research Site

    Bakersfield, California

  • Regeneron Research Site

    Long Beach, California

  • Regeneron Research Site

    Mission Viejo, California

  • Regeneron Research Site

    Rolling Hills Estates, California

  • Regeneron Research Site

    San Diego, California

  • Regeneron Research Site

    Denver, Colorado

  • Regeneron Research Site

    Coral Gables, Florida

  • Regeneron Research Site

    Tampa, Florida

  • Regeneron Research Site

    Tampa, Florida

  • Regeneron Research Site

    Macon, Georgia

  • Regeneron Research Site

    Sandy Springs, Georgia

  • Regeneron Research Site

    Chicago, Illinois

  • Regeneron Research Site

    Normal, Illinois

  • Regeneron Research Site

    Rockville, Maryland

  • Regeneron Research Site

    Ypsilanti, Michigan

  • Regeneron Research Site

    Minneapolis, Minnesota

  • Regeneron Research Site

    St Louis, Missouri

  • Regeneron Research Site

    Forest Hills, New York

  • Regeneron Research Site

    New York, New York

  • Regeneron Research Site

    Rochester, New York

  • Regeneron Research Site

    Gahanna, Ohio

  • Regeneron Research Site

    Portland, Oregon

  • Regeneron Research Site

    Philadelphia, Pennsylvania

  • Regeneron Research Site

    Charleston, South Carolina

  • Regeneron Research Site

    North Charleston, South Carolina

  • Regeneron Research Site

    Bellaire, Texas

  • Regeneron Research Site

    San Antonio, Texas

  • Regeneron Research Site

    Norfolk, Virginia

  • Regeneron Research Site

    Seattle, Washington

  • Regeneron Research Site

    Calgary, Alberta, Canada

  • Regeneron Research Site

    Markham, Ontario, Canada

  • Regeneron Research Site

    Peterborough, Ontario, Canada

  • Regeneron Research Site

    Montreal, Quebec, Canada

  • Regeneron Research Site

    Kutná Hora, Czechia

  • Regeneron Research Site

    Ústí nad Labem, Czechia

  • Regeneron Research Site

    Bad Bentheim, Germany

  • Regeneron Research Site

    Hamburg, Germany

  • Regeneron Research Site

    Munich, Bavaria, Germany

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.